InMed to merge with Mentari; pre-Merger InMed holders to own ~1.51% of combined company

InMed Pharmaceuticals Inc.

Merger: InMed shareholders to own ~1.51% of combined entity; Mentari stockholders ~98.49%.
Concurrent $290M private placement led by Fairmount; funds operations through 2028.
Mentari's lead programs: MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) targeting migraine prevention.
Pre-Merger InMed shareholders receive Contingent Value Rights (CVRs) for net proceeds from legacy asset sales.
Closing conditions include $150M+ pre-closing financing, shareholder approvals, and Nasdaq listing.

item 1.01 item 5.01 item 5.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

InMed Pharmaceuticals Inc. entered into Agreement and Plan of Merger and Reorganization with Mentari Therapeutics, Inc. valued at equity value of $125,000,000 (effective 2026-05-19).

Action: entry
Agreement: merger
Counterparty: Mentari Therapeutics, Inc.
Value: equity value of $125,000,000
Effective: 2026-05-19

Exact text from the filing

ub, the “ Merger Subs ”), and Mentari Therapeutics, Inc., a Delaware corporation (“ Mentari ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”), pursuant to which, among other matters

View on SEC.gov

197 material agreements filed in the last 30 days. Browse all material agreements →

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-058795

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.